ArticleJournal of pharmaceutical sciences2018
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.
Article in Journal of pharmaceutical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Injectable Hydrogels for Local Pharmacokinetic Control in Solid Tumors: From Passive Reservoirs to Stimulus-Responsive Exposure Systems.ACS pharmacology & translational science · 2026Review
- Locoregional Delivery of miRNAs for Glioblastoma Treatment: A Systematic Review of Advances in Delivery Systems.Pharmaceutics · 2026Review
- Bio-Polymers Based Functionalized Hydrogel Carriers for Targeted Oncology Therapies: Current Progress and Future Perspectives.International journal of nanomedicine · 2026Review
- Hydrogel-based nanoparticles: revolutionizing brain tumor treatment and paving the way for future innovations.European journal of medical research · 2025Review
- The function of TRIML2 on the temozolomide resistance in glioblastoma.Annals of medicine and surgery (2012) · 2025Article
- Advances in Hydrogels of Drug Delivery Systems for the Local Treatment of Brain Tumors.Gels (Basel, Switzerland) · 2024Review
- Advancements in Regenerative Hydrogels in Skin Wound Treatment: A Comprehensive Review.International journal of molecular sciences · 2024Review
- A Big Prospect for Hydrogel Nano-System in Glioma.International journal of nanomedicine · 2024Review
- Peritumoral brain zone in glioblastoma: biological, clinical and mechanical features.Frontiers in immunology · 2024Review
- Exploring the vast potentials and probable limitations of novel and nanostructured implantable drug delivery systems for cancer treatment.EXCLI journal · 2024Review
- An Innovative Polymeric Platform for Controlled and Localized Drug Delivery.Pharmaceutics · 2023Article
- Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models.Scientific reports · 2023Article
- Self-Healing Injectable Hydrogels for Tissue Regeneration.Chemical reviews · 2023Review
- Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment.Theranostics · 2023Review
- Hydrogels for localized chemotherapy of liver cancer: a possible strategy for improved and safe liver cancer treatment.Drug delivery · 2022Article
- Intranasal delivery in glioblastoma treatment: prospective molecular treatment modalities.Heliyon · 2022Review
- Advances in local therapy for glioblastoma - taking the fight to the tumour.Nature reviews. Neurology · 2022Review
- Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma.International journal of molecular sciences · 2021Review
- Microfluidic Chip Device forLangmuir : the ACS journal of surfaces and colloids · 2021Article
- Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile.International journal of radiation oncology, biology, physics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Overall survival of patients with newly diagnosed glioblastoma (GBM) remains dismal at 16 months with state-of-the-art treatment that includes surgical resection, radiation, and chemotherapy. GBM tumors are highly heterogeneous, and mechanisms for overcoming tumor resistance have not yet fully been elucidated. An injectable chitosan hydrogel capable of releasing chemotherapy (temozolomide [TMZ]) while retaining radioactive isotopes agents (iodine, [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.